InnoPharmax Stock Forecast - Naive Prediction
| 4172 Stock | TWD 17.05 0.80 4.92% |
InnoPharmax Stock outlook is based on your current time horizon.
As of today the value of rsi of InnoPharmax's share price is below 20 . This suggests that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Using InnoPharmax hype-based prediction, you can estimate the value of InnoPharmax from the perspective of InnoPharmax response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of InnoPharmax on the next trading day is expected to be 16.32 with a mean absolute deviation of 0.34 and the sum of the absolute errors of 14.05. InnoPharmax after-hype prediction price | TWD 16.75 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
InnoPharmax |
InnoPharmax Additional Predictive Modules
Most predictive techniques to examine InnoPharmax price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for InnoPharmax using various technical indicators. When you analyze InnoPharmax charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
InnoPharmax Naive Prediction Price Forecast For the 29th of January
Given 90 days horizon, the Naive Prediction forecasted value of InnoPharmax on the next trading day is expected to be 16.32 with a mean absolute deviation of 0.34, mean absolute percentage error of 0.24, and the sum of the absolute errors of 14.05.Please note that although there have been many attempts to predict InnoPharmax Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that InnoPharmax's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
InnoPharmax Stock Forecast Pattern
| Backtest InnoPharmax | InnoPharmax Price Prediction | Buy or Sell Advice |
InnoPharmax Forecasted Value
In the context of forecasting InnoPharmax's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. InnoPharmax's downside and upside margins for the forecasting period are 12.87 and 19.76, respectively. We have considered InnoPharmax's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of InnoPharmax stock data series using in forecasting. Note that when a statistical model is used to represent InnoPharmax stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 79.9158 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.3427 |
| MAPE | Mean absolute percentage error | 0.0196 |
| SAE | Sum of the absolute errors | 14.0506 |
Predictive Modules for InnoPharmax
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as InnoPharmax. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.InnoPharmax After-Hype Price Density Analysis
As far as predicting the price of InnoPharmax at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in InnoPharmax or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of InnoPharmax, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
InnoPharmax Estimiated After-Hype Price Volatility
In the context of predicting InnoPharmax's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on InnoPharmax's historical news coverage. InnoPharmax's after-hype downside and upside margins for the prediction period are 13.29 and 20.21, respectively. We have considered InnoPharmax's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
InnoPharmax is not too volatile at this time. Analysis and calculation of next after-hype price of InnoPharmax is based on 3 months time horizon.
InnoPharmax Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as InnoPharmax is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading InnoPharmax backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with InnoPharmax, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.14 | 3.45 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | In 5 to 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
17.05 | 16.75 | 0.00 |
|
InnoPharmax Hype Timeline
InnoPharmax is presently traded for 17.05on Taiwan OTC Exchange of Taiwan. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. InnoPharmax is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is presently at 0.14%. %. The volatility of related hype on InnoPharmax is about 0.0%, with the expected price after the next announcement by competition of 17.05. The company has Price-to-Book (P/B) ratio of 1.34. In the past many companies with similar price-to-book ratios have beat the market. InnoPharmax recorded a loss per share of 1.23. The entity had not issued any dividends in recent years. Assuming the 90 days trading horizon the next anticipated press release will be in 5 to 10 days. Check out Historical Fundamental Analysis of InnoPharmax to cross-verify your projections.InnoPharmax Related Hype Analysis
Having access to credible news sources related to InnoPharmax's direct competition is more important than ever and may enhance your ability to predict InnoPharmax's future price movements. Getting to know how InnoPharmax's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how InnoPharmax may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| 6817 | Winston Medical Supply | 0.00 | 0 per month | 0.00 | (0.19) | 3.25 | (3.18) | 8.49 | |
| 3054 | LIWANLI Innovation Co | 0.00 | 0 per month | 1.25 | 0.18 | 3.97 | (2.54) | 14.35 | |
| 8432 | tsh biopharmoration | 0.00 | 0 per month | 1.05 | (0.01) | 1.85 | (1.45) | 8.37 | |
| 4132 | Golden Biotechnology | 0.00 | 0 per month | 4.61 | 0.12 | 12.15 | (6.05) | 45.53 | |
| 1780 | Allied Biotech | 0.00 | 0 per month | 1.49 | 0.03 | 2.88 | (2.49) | 14.51 | |
| 1762 | Chunghwa Chemical Synthesis | 0.00 | 0 per month | 0.61 | (0.02) | 2.01 | (1.16) | 4.75 | |
| 1796 | GeneFerm Biotechnology Co | 0.00 | 0 per month | 0.00 | (0.14) | 2.58 | (2.83) | 7.77 | |
| 6709 | Advagene Biopharma Co | 0.00 | 0 per month | 0.00 | (0.09) | 3.82 | (3.71) | 16.90 | |
| 6130 | Singbao International Co | 0.00 | 0 per month | 2.21 | (0.03) | 3.95 | (3.93) | 14.17 | |
| 6676 | Sunny Pharmtech | 0.00 | 0 per month | 1.94 | 0.1 | 3.96 | (3.58) | 22.10 |
Other Forecasting Options for InnoPharmax
For every potential investor in InnoPharmax, whether a beginner or expert, InnoPharmax's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. InnoPharmax Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in InnoPharmax. Basic forecasting techniques help filter out the noise by identifying InnoPharmax's price trends.InnoPharmax Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with InnoPharmax stock to make a market-neutral strategy. Peer analysis of InnoPharmax could also be used in its relative valuation, which is a method of valuing InnoPharmax by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
InnoPharmax Market Strength Events
Market strength indicators help investors to evaluate how InnoPharmax stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading InnoPharmax shares will generate the highest return on investment. By undertsting and applying InnoPharmax stock market strength indicators, traders can identify InnoPharmax entry and exit signals to maximize returns.
| Accumulation Distribution | 34008.45 | |||
| Daily Balance Of Power | 0.8 | |||
| Rate Of Daily Change | 1.05 | |||
| Day Median Price | 16.9 | |||
| Day Typical Price | 16.95 | |||
| Price Action Indicator | 0.55 | |||
| Period Momentum Indicator | 0.8 |
InnoPharmax Risk Indicators
The analysis of InnoPharmax's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in InnoPharmax's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting innopharmax stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 2.42 | |||
| Semi Deviation | 2.43 | |||
| Standard Deviation | 3.46 | |||
| Variance | 11.97 | |||
| Downside Variance | 6.79 | |||
| Semi Variance | 5.9 | |||
| Expected Short fall | (3.56) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for InnoPharmax
The number of cover stories for InnoPharmax depends on current market conditions and InnoPharmax's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that InnoPharmax is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about InnoPharmax's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
InnoPharmax Short Properties
InnoPharmax's future price predictability will typically decrease when InnoPharmax's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of InnoPharmax often depends not only on the future outlook of the potential InnoPharmax's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. InnoPharmax's indicators that are reflective of the short sentiment are summarized in the table below.
| Average Daily Volume Last 10 Day | 182.84k | |
| Average Daily Volume In Three Month | 182.2k |
Additional Tools for InnoPharmax Stock Analysis
When running InnoPharmax's price analysis, check to measure InnoPharmax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InnoPharmax is operating at the current time. Most of InnoPharmax's value examination focuses on studying past and present price action to predict the probability of InnoPharmax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InnoPharmax's price. Additionally, you may evaluate how the addition of InnoPharmax to your portfolios can decrease your overall portfolio volatility.